Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer
Primary Purpose
High Grade Ovarian Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Biospecimen Collection
Laboratory Biomarker Analysis
Lavage
Pap Smear
Sponsored by
About this trial
This is an interventional diagnostic trial for High Grade Ovarian Serous Adenocarcinoma
Eligibility Criteria
Inclusion Criteria:
- With suspected advanced ovarian cancer
- Planned surgery
- Have a uterus and no history of tubal occlusion
Exclusion Criteria:
- Unable to speak English
- Unable to provide informed consent
- Prior hysterectomy
Sites / Locations
- Fred Hutch/University of Washington Cancer Consortium
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Diagnostic (pap smear, uterine lavage, tumor sample)
Arm Description
Participants undergo pap smear, uterine lavage, and collection of tumor sample during a planned surgery. DNA is then extracted from the samples and sequenced for TP53 mutations using Crispr-Duplex sequencing.
Outcomes
Primary Outcome Measures
Sensitivity of pap smear versus sensitivity of uterine lavage in detection of tumor-derived TP53 mutations
Pap smear and uterine lavage samples will be sequenced for TP53 mutations using the Crispr-Duplex Sequencing method. Primary tumors will be sequenced in order to confirm that the mutations identified in the Pap and/or uterine lavage are present in the tumor.
Specificity of pap smear versus specificity of uterine lavage in detection of tumor-derived TP53 mutations
Pap smear and uterine lavage samples will be sequenced for TP53 mutations using the Crispr-Duplex Sequencing method. Primary tumors will be sequenced in order to confirm that the mutations identified in the Pap and/or uterine lavage are present in the tumor.
Secondary Outcome Measures
Full Information
NCT ID
NCT03606486
First Posted
July 20, 2018
Last Updated
January 18, 2023
Sponsor
University of Washington
Collaborators
Minnesota Ovarian Cancer Alliance
1. Study Identification
Unique Protocol Identification Number
NCT03606486
Brief Title
Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer
Official Title
Lavage of the Uterine Cavity for Diagnosis of Ovarian Carcinomas
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Terminated
Why Stopped
Terminated due to low accrual
Study Start Date
November 16, 2018 (Actual)
Primary Completion Date
December 9, 2022 (Actual)
Study Completion Date
December 9, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Washington
Collaborators
Minnesota Ovarian Cancer Alliance
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
5. Study Description
Brief Summary
The goal of this project is to develop a minimally invasive test to detect ovarian cancer, by searching for mutations from the tumor in samples obtained from the cervix (Pap smears), and from the uterus (uterine lavage) in women with advanced ovarian cancer. The investigators plan a pilot study of 25 women with advanced ovarian cancer. Pap smear and uterine lavage samples will be collected while the woman is under anesthesia for planned debulking surgery. A novel, highly sensitive and accurate technique, Crispr-Duplex sequencing, will be used to detect tumor associated mutations in TP53 (the most commonly mutated gene in ovarian cancer) within these samples. These results will be compared to sequencing results in the tumor itself for comparison, and Pap and uterine lavage will be compared to each other to determine the optimal test. Ultimately, the goal is to use the results of this study to plan a larger study including women without cancer who are at either increased risk or normal risk of ovarian cancer, for use in early detection.
Detailed Description
OUTLINE:
Participants undergo pap smear, uterine lavage, and collection of tumor sample during a planned surgery. DNA is then extracted from the samples and sequenced for TP53 mutations using Crispr-Duplex sequencing.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
High Grade Ovarian Serous Adenocarcinoma, Stage III Ovarian Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
52 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Diagnostic (pap smear, uterine lavage, tumor sample)
Arm Type
Experimental
Arm Description
Participants undergo pap smear, uterine lavage, and collection of tumor sample during a planned surgery. DNA is then extracted from the samples and sequenced for TP53 mutations using Crispr-Duplex sequencing.
Intervention Type
Other
Intervention Name(s)
Biospecimen Collection
Intervention Description
Undergo collection of tumor sample and blood draw
Intervention Type
Other
Intervention Name(s)
Laboratory Biomarker Analysis
Intervention Description
Correlative studies
Intervention Type
Device
Intervention Name(s)
Lavage
Other Intervention Name(s)
Irrigation
Intervention Description
Undergo uterine lavage
Intervention Type
Other
Intervention Name(s)
Pap Smear
Other Intervention Name(s)
Cervical Smear Preparation, Cervical Smear Procedure, Pap Smear Procedure, Pap Test, Papanicolaou Smear Procedure, Papanicolaou Test, Vaginal Smears
Intervention Description
Undergo pap smear
Primary Outcome Measure Information:
Title
Sensitivity of pap smear versus sensitivity of uterine lavage in detection of tumor-derived TP53 mutations
Description
Pap smear and uterine lavage samples will be sequenced for TP53 mutations using the Crispr-Duplex Sequencing method. Primary tumors will be sequenced in order to confirm that the mutations identified in the Pap and/or uterine lavage are present in the tumor.
Time Frame
Up to 1 year
Title
Specificity of pap smear versus specificity of uterine lavage in detection of tumor-derived TP53 mutations
Description
Pap smear and uterine lavage samples will be sequenced for TP53 mutations using the Crispr-Duplex Sequencing method. Primary tumors will be sequenced in order to confirm that the mutations identified in the Pap and/or uterine lavage are present in the tumor.
Time Frame
Up to 1 year
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
With suspected advanced ovarian cancer or genetic predisposition to malignant neoplasm of the ovary
Planned surgery
Have a uterus and no history of tubal occlusion
Exclusion Criteria:
Unable to speak English
Unable to provide informed consent
Prior hysterectomy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Barbara S. Norquist
Organizational Affiliation
Fred Hutch/University of Washington Cancer Consortium
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rosana Risques
Organizational Affiliation
Fred Hutch/University of Washington Cancer Consortium
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fred Hutch/University of Washington Cancer Consortium
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer
We'll reach out to this number within 24 hrs